Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosaprepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 18/20 | 0.59 |
| ▸ | TACR3 | P29371 | 2/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | FPR1 | P21462 | 1/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosaprepitant SCHEMBL17837327 | 1.00 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL22076807 | 1.00 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL30861885 | 1.00 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL1932400 | 0.92 | TACR1 (0.57) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL21955651 | 0.91 | TACR1 (0.71) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL1651366 | 0.91 | TACR1 (0.71) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL20473749 | 0.90 | TACR1 (0.60) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL21391935 | 0.89 | TACR1 (0.57) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL22076806 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL156379 | 0.89 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2022-01-13 | — | — | US | disclosed |
| EP-3763366-A1 | ROFLUMILAST N-OXIDE FOR USE IN TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION | Incozen Therapeutics Pvt. Ltd. (IN) | 2021-01-13 | — | — | EP | disclosed |
| EP-2948148-B1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3024459-B1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL, S.A. (ES) | 2018-07-19 | — | — | US | disclosed |
| US-20170196843-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2017-07-13 | — | — | US | disclosed |
| US-9649302-B2 | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast N-oxide | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-05-16 | — | — | US | disclosed |
| US-20160038470-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | GRAS ESCARDO JORDI (ES) | 2016-02-11 | — | — | US | disclosed |
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ALMIRALL, S.A. (ES) | 2016-01-21 | — | — | US | disclosed |
| US-20150306079-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2015-10-29 | — | — | US | disclosed |
| EP-1891973-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045565-A1 | Combinations Comprising Antimuscarinic Agents and Beta-Adrenergic Agonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-21 | — | — | US | disclosed |
| US-20070232637-A1 | Combinations Comprising Antimuscarinic Agents and Pde4 Inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-10-04 | — | — | US | disclosed |
| US-20070167489-A1 | Combination comprising antimuscarinic agents and PDE4 inhibitors | GRAS ESCARDO JORDI | 2007-07-19 | — | — | US | disclosed |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-09-14 | — | — | US | disclosed |
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-24 | — | — | US | disclosed |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-07-13 | — | — | US | disclosed |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | GRAS ESCARDO JORDI | 2005-12-29 | — | — | US | disclosed |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | ESCARDO JORDI G | 2005-12-01 | — | — | US | disclosed |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | GRAS ESCARDO JORDI | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | NOS3, NOS2, NOS1 | TACR1 1131/4885TACR3 1848/4885NR3C1 885/4885 |
| US-20060189651-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20080045565-A1 | Combinations Comprising Antimuscarinic Agents and Beta-Adrenergic Agonists | CHRM3, ADRB2, CHRM2 | TACR1 78/4885TACR3 142/4885NR3C1 626/4885 |
| US-20180200234-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 213/4885NR3C1 591/4885 |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | TACR1 72/4885TACR3 117/4885NR3C1 282/4885 |
| US-20070167489-A1 | Combination comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 215/4885NR3C1 596/4885 |
| US-20150306079-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, PDE4A, CHRM4 | TACR1 156/4885TACR3 182/4885NR3C1 642/4885 |
| US-20160015704-A1 | COMBINATIONS COMPRISING MABA COMPOUNDS AND CORTICOSTEROIDS | ADRB2, ADRA2A, ADRA2B | TACR1 810/4885TACR3 641/4885NR3C1 15/4885 |
| US-20170196843-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | NOS3, NOS2, NOS1 | TACR1 1131/4885TACR3 1848/4885NR3C1 885/4885 |
| US-20060154934-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | TACR1 141/4885TACR3 213/4885NR3C1 591/4885 |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | TACR1 67/4885TACR3 153/4885NR3C1 18/4885 |
| US-20070232637-A1 | Combinations Comprising Antimuscarinic Agents and Pde4 Inhibitors | CHRM3, CHRM4, PDE4A | TACR1 121/4885TACR3 125/4885NR3C1 1509/4885 |
| US-20160038470-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | CHRM3, CHRM2, CHRM1 | TACR1 67/4885TACR3 153/4885NR3C1 18/4885 |
| US-20050288266-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | TACR1 67/4885TACR3 153/4885NR3C1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.